|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD97 promotes gastric cancer cell proliferation and invasion in vitro through exosome-mediated MAPK signaling pathway, and exosomal miRNAs are probably involved in activation of the CD97-associated pathway.
|
26034356 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 is a tumor-associated adhesion-class G-protein-coupled receptor involved in modulating cell migration.
|
25174588 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126.
|
24274104 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors were strongly CD97-positive, independent of the underlying histological subtype, suggesting high sensitivity of CD97 for this tumor.
|
24949957 |
2014 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We discovered a new direct target of miR-126: CD97, a pro-metastatic G-protein-coupled receptor (GPCR) that has been reported to promote tumor cell invasion, endothelial cell migration, and tumor angiogenesis.
|
24274104 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This phenotype may explain the discrepancy in survival between high and low CD97-expressing tumors.
|
23658650 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of transgenic CD97 in thyroid epithelium led to elevated ERK phosphorylation and increased numbers of Ki67+ cells in developing tumors.
|
22797060 |
2013 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In this study we show that CD97 is expressed in glioma, has functional effects on invasion, and is associated with poor overall survival.
|
23658650 |
2013 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.
|
22768192 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
One candidate target, CD97, was then selected for further investigation into its role by suppressing its expression using siRNA silencing, followed by proliferation and invasion assays.
|
22313360 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, EMR2 nuclear expression correlated negatively with higher tumour grade.
|
21174063 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on an analysis showing earlier mortality among glioblastoma patients whose tumors highly express EMR2, we studied its expression patterns in glioblastoma and potential to mediate cellular proliferation and invasion.
|
21503828 |
2011 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD97 functioned to mediate invasion in prostate cancer cells, at least in part, by associating with lysophosphatidic acid receptor 1 (LPAR1), leading to enhanced LPA-dependent RHO and extracellular signal-regulated kinase activation.
|
21978933 |
2011 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We then employed siRNA knockdown of EMR2 in two human glioblastoma cell lines expressing high levels of EMR2 to assess functional effects on cellular proliferation and invasion, in vitro.
|
21503828 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The study further lightened the tumor promoting role of CD97 small isoform in cancer progression and indicated the possible suppressive properties of the full length isoform of CD97.
|
20428763 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show here that CD97alpha promotes angiogenesis in vivo as demonstrated with purified protein in a directed in vivo angiogenesis assay (DIVAA) and by enhanced vascularization of developing tumors expressing CD97.
|
15576472 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was strong correlation between the distribution patterns of CD97(stalk) and CD55 on tumor tissues (r=0.73, P<0.05).
|
16130195 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that CD97(stalk) is probably involved in the growth, invasion and aggressiveness of gastric carcinomas by binding its cellular ligand CD55.
|
16130195 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It was found that coengagement of alpha5beta1 and chondroitotin sulfate proteoglycan by CD97 synergistically initiates endothelial cell invasion.
|
15576472 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of CD97(EGF) in the margins showed a marked difference between the depth of tumor invasion T1 and T2, 3 and 4, and stages I and II/III/IV of gastric carcinomas (P<0.05).
|
16273233 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoprecipitation of CD97 from the Colo 205 tumor cell line revealed the established 78 and 83 kDa products, while a 52 and 57 kDa band were obtained from smooth muscle cells.
|
15386373 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast to CD97, which is found in most colorectal adenocarcinomas, only 8 of 81 of these tumors expressed EMR2.
|
12761622 |
2003 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
EMR2 expression did not correlate with in vitro migration or invasion capacity of the cell lines.
|
12761622 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, intralobular and interlobular pancreatic ducts were CD97+.All tumors were EMR2-.
|
12428789 |
2002 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The level of CD97 in each line correlated with migration and invasion in vitro.
|
12414513 |
2002 |